Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs

2.1 Guselkumab (Tremfya, Janssen), 'alone or in combination with methotrexate (MTX), is indicated for the treatment of active psoriatic arthritis in adult patients who have had an inadequate response or who have been intolerant to a prior disease-modifying antirheumatic drug (DMARD) therapy'.

2.2 The dosage schedule is available in the summary of product characteristics for guselkumab.

2.3 The cost of a 100 mg pre-filled disposable injection of guselkumab is £2,250.00 (excluding VAT; BNF online, accessed May 2022). The company has a commercial arrangement. This makes guselkumab available to the NHS with a discount. The size of the simple patient access scheme discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount. In the complex patient access scheme, the 4‑weekly regimen is provided at the same cost as an 8‑weekly regimen. If every 4 weeks dosing is needed, the price will be equalised with every 8 weeks dosing by supplying 2 of the 100 mg pre‑filled disposable injections for the price of 1.